AstraZeneca's Ultomiris sustains function improvement over 1 year in muscle disorder patients

Retrieved on: 2022-04-06 10:41:11

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca's Ultomiris sustains function improvement over 1 year in muscle disorder patients. View article details on hiswai:

Excerpt

AstraZeneca (AZN) said Ultomiris helped improve activities of daily living, muscle strength and quality of life through 60 weeks in patients with ...

Article found on: seekingalpha.com